サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：狂犬病免疫グロブリン市場2022-2028
市場調査レポート
商品コード
1215774

狂犬病免疫グロブリン市場2022-2028

Rabies Immunoglobulin Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
狂犬病免疫グロブリン市場2022-2028
出版日: 2023年01月20日
発行: Orion Market Research
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の狂犬病免疫グロブリン市場は、予測期間中に6.1%の大幅なCAGRで成長すると予想されています。主要なプレーヤーに対するFDA承認の増加は、予測期間中に市場を積極的にサポートすることが期待されます。例えば、2021年6月、小児集団におけるKEDRABの安全性と有効性に基づく新たなFDA承認が、米国の市販後臨床試験で実証されました。Kedrion BiopharmaとKamada Ltd.は、血漿由来タンパク質治療薬に注力する2つの主要なバイオ製薬会社で、KEDRAB（Rabies Immune Globulin（Human））のラベル更新をFDAが承認し、同製品の子供における安全性と有効性が確立したと発表しました。

世界の狂犬病免疫グロブリン市場は、タイプに基づいて区分されています。タイプに基づき、市場はHRIGとERIGに区分されます。ERIGは馬用RIGであり、馬で生産されます。世界保健機関（WHO）によると、安価で安全な（精製ペプシン消化馬血清）馬免疫グロブリン（ERIG）は限られた量しか入手できず、ほとんどの状況で、最も必要とする人がアクセスできない状態になっているそうです。したがって、予測期間中の市場成長は制限されます。さまざまな種類の馬抗狂犬病免疫グロブリン（ERIG）が、通常は狂犬病ウイルスの不活性化株と固定株の組み合わせからなる、さまざまな免疫原性製剤を用いて製造されてきました。

地域的には、世界の狂犬病免疫グロブリン市場は、北米、欧州、アジア太平洋地域、その他の地域に区分されます。北米地域は、医療インフラが整備されており、複数の企業が進出していることから、予測期間中、市場で突出したシェアを占めると予想されます。同地域の人々は狂犬病についてよく理解しているため、予測期間中に狂犬病免疫グロブリン市場を促進することが期待されます。CDCによると、2021年に米国で5人が狂犬病で死亡し、2年間の狂犬病患者報告ゼロに続き、年間報告数としては最高となっています。さらに、米国での狂犬病による死亡はまれであり、通常、年間1～3件の症例が報告されています。

目次

第1章 レポート概要

  • 現在の産業分析と成長性の展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要とインサイト

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • レコメンデーション
    • まとめ

第3章 競合情勢

  • 主要企業の分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 狂犬病免疫グロブリンの世界市場：タイプ別
    • ヒト狂犬病免疫グロブリン（HRIG）
    • 馬用狂犬病免疫グロブリン（ERIG）

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他の欧州
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Bharat Serums and Vaccines Ltd.（BSV）
  • CSL Behring
  • Grifols SA
  • Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • Haffkine Bio-Pharmaceutical Corp. LTD.
  • Kamada Ltd.
  • Lanzhou Institute Of Biological Products Co., Ltd.
  • Premium Serums and Vaccines Pvt.Ltd.（PSVPL）
  • Sanofi SA
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shanghai Serum Bio-technology Co., LTD.
  • Shenzhen Weiguang Biological Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • Sun Pharmaceuticals Co. Ltd.
  • VINS Bioproducts Ltd
図表

LIST OF TABLES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL HUMAN RABIES IMMUNE GLOBULIN (HRIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL EQUINE RABIES IMMUNO GLOBULIN (ERIG) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 6. NORTH AMERICAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 7. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 8. EUROPEAN RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 9. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 10. ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 11. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL HRIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 3. GLOBAL ERIG MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL RABIES IMMUNOGLOBULIN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. US RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 6. CANADA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 7. UK RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 8. FRANCE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. GERMANY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. ITALY RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. SPAIN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. REST OF EUROPE RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. INDIA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. CHINA RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. JAPAN RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RABIES IMMUNOGLOBULIN MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026830

Title:Global Rabies Immunoglobulin Market Size, Share & Trends Analysis Report by Type (Human Rabies Immune Globulin (HRIG) and Equine Rabies Immuno Globulin (ERIG)) Forecast Period (2022-2028).

The global rabies immunoglobulin market is anticipated to grow at a substantial CAGR of 6.1% during the forecast period. The increasing FDA approvals to key players are expected to support the market positively during the forecast period. For instance, in June 2021, new FDA Approval based on the safety and effectiveness of KEDRAB in the pediatric population was demonstrated in a US post-marketing clinical trial. Kedrion Biopharma and Kamada Ltd., are two key biopharmaceutical companies focused on plasma-derived protein therapeutics announced the FDA approved a label update for KEDRAB (Rabies Immune Globulin (Human)), establishing the product's safety and effectiveness in children.

The global rabies immunoglobulin market is segmented based on type. Based on the type, the market is segmented into HRIG and ERIG. ERIG is an equine RIG and is produced in horses. According to the World Health Organization (WHO), cheaper and safe (purified pepsin digested horse serum) equine immunoglobulin (ERIG) is available in limited quantities and most situations are inaccessible to those that need it most. Thus, limiting the market growth during the forecast period. Different types of equine antirabies immunoglobulin (ERIG) have been produced using various immunogenic preparations, consisting usually of a combination of inactivated and fixed strains of rabies virus.

Geographically, the global rabies immunoglobulin market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The North American region is expected to hold a prominent share in the market during the forecast period due to the well-developed healthcare infrastructure and presence of several players in the region. The people in the region are well aware of rabies disease which is expected to propel the rabies immunoglobulin market during the forecast period. According to the CDC, five people died of rabies in the US in 2021, and following two years of zero rabies cases reported in the US and is the highest number reported per year. Further, rabies deaths in the U.S. are rare, with typically one to three cases reported annually.

The major companies serving the global rabies immunoglobulin market include Bharat Serums and Vaccines Ltd. (BSV), CSL Behring, Grifols SA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2019, Kamada Ltd., a plasma-derived protein therapeutics company entered into a binding term sheet for a 12-year contract manufacturing agreement with an undisclosed partner to manufacture a US Food and Drug Administration (FDA) approved and commercialized specialty hyper-immune globulin product. Following the execution of the required technology transfer from the current manufacturer, and pending obtaining all required FDA approvals, Kamada is expected to commence commercial manufacturing of the product in early 2023.

Research Methodology

The market study of the global rabies immunoglobulin market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Rabies Immunoglobulin Market Research and Analysis by Type.

The Report Covers:

  • Comprehensive research methodology of the global rabies immunoglobulin market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global rabies immunoglobulin market.
  • Insights about market determinants that are stimulating the global rabies immunoglobulin market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Rabies Immunoglobulin Market by Type
    • 4.1.1. Human Rabies Immune Globulin (HRIG)
    • 4.1.2. Equine Rabies Immunoglobulin (ERIG)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. US
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Bharat Serums and Vaccines Ltd. (BSV)
  • 6.2. CSL Behring
  • 6.3. Grifols SA
  • 6.4. Guangdong Shuanglin Bio-Pharmacy Co, Ltd.
  • 6.5. Haffkine Bio-Pharmaceutical Corp. LTD.
  • 6.6. Kamada Ltd.
  • 6.7. Lanzhou Institute Of Biological Products Co., Ltd.
  • 6.8. Premium Serums and Vaccines Pvt.Ltd. (PSVPL)
  • 6.9. Sanofi SA
  • 6.10. Shanghai RAAS Blood Products Co., Ltd.
  • 6.11. Shanghai Serum Bio-technology Co., LTD.
  • 6.12. Shenzhen Weiguang Biological Products Co., Ltd.
  • 6.13. Sichuan Yuanda Shuyang Pharmaceutical CO., Ltd.
  • 6.14. Sun Pharmaceuticals Co. Ltd.
  • 6.15. VINS Bioproducts Ltd